HEPARIN CALCIUM MARKET ANALYSIS

Heparin Calcium Market, by Type (Unfractionated Heparin and Low Molecular Weight Heparin), by Route of Administration (Intravenous and Subcutaneous), by Application (Kidney Dialysis, Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Others (Cardiac Surgery, etc.)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023
Code : CMI5483
Pages :180
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Heparin Calcium Market: Key Developments

Ongoing research and development by key market players is expected to drive the heparin calcium market over the forecast period. For instance, in December 2022, Galician Research Group on Digestive Tumors in collaboration with LEO Pharma A/S, a pharmaceutical company, started a clinical trial for to evaluate the efficacy of tinzaparin (low molecular weight heparin) for the prevention of symptomatic venous thromboembolic disease. The trial is expected to complete in March 2025.
Increasing adoption of inorganic growth strategies such as product approval by regulatory authorities such as the U.S. Food and Drug Administration is expected to drive the global heparin calcium market growth over the forecast period. For instance, in June 2021, Boehringer Ingelheim Pharmaceuticals, Inc., a pharmaceutical company, announced that they had received an approval from the U.S. Food and Drug Administration for Dabigatran, an anticoagulant for children from 3 months to 11 years old to treat deep vein thrombosis.

Global Heparin Calcium Market: Key Trends

Ongoing Research and Development on calcium heparin is expected to drive the hea[prin calcium market over the forecast period.

Ongoing Research and Development on calcium heparin is expected to drive the hea[prin calcium market over the forecast period.For instance, on September 27, 2022, Anthos Therapeutics, a biopharmaceutical company, announced that they had started a clinical trial on Dalteparin, a low-molecular weight heparin, for the treatment of deep vein thrombosis.

Global Heparin Calcium Market: Restraint

Various side affects associated with the use of heparin calcium is expected to hinder the global heparin calcium market over the forecast period.